The natural product berberine is a human prolyl oligopeptidase inhibitor

被引:65
|
作者
Tarrago, Teresa
Kichik, Nessim
Segui, Josep
Giralt, Ernest
机构
[1] Institut de Recerca Biomèdica de Barcelona, Parc Científic de Barcelona, 08028 Barcelona, Josep Samitier
[2] Departament de Bioquímica, Universitat de Barcelona, 08028 Barcelona, Avda. Diagonal
[3] Departament de Química Orgànica, Universitat de Barcelona, 08028 Barcelona, Martí Franqués
关键词
Berberine; Fluorine NMR spectroscopy; Prolyl oligopeptidase; Schizophrenia; Traditional Chinese medicine;
D O I
10.1002/cmdc.200600303
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Prolyl oligopeptidase is a cytosolic serine peptidase that hydrolyzes proline-containing peptides at the carboxy terminus. This peptidase has been associated with schizophrenia, bipolar affective disorder, and related neuropsychiatric disorders, and therefore may have important clinical implications. Among the strategies used to find novel prolyl oligopeptidase inhibitors, traditional Chinese medicinal plants provide a rich source of unexplored compounds. We used F-19 NMR spectroscopy to search for new prolyl oligopeptidase inhibitors in a library of traditional Chinese medicine plant extracts. Several extracts were identified as powerful inhibitors of this peptidase. The alkaloid berberine was the prolyl oligopeptidase inhibitory molecule isolated from Rhizoma coptidis extract. Berberine inhibited prolyl oligopeptidose in a dose-dependent manner. As berberine is a natural compound that has been safely administered to humans, it opens up new perspectives for the treatment of neuropsychiatric diseases. The results described herein suggest that the initiation of clinical trials in patients with schizophrenia, bipolar affective disorder, or related diseases in which cognitive capabilities are affected should be undertaken with either the extract or pure BBR.
引用
收藏
页码:354 / 359
页数:6
相关论文
共 50 条
  • [41] Identification of the natural product berberine as an antiviral drug
    Jiping Shao
    Debin Zeng
    Shuhong Tian
    Gezhi Liu
    Jian Fu
    AMB Express, 10
  • [42] Prolyl oligopeptidase inhibitor KYP-2047 alleviates inflammation in retinal pigment epithelium cells
    Toppila, Maija
    Ranta-Aho, Sofia
    Bhattarai, Niina
    Korhonen, Eveliina
    Hytti, Maria
    Kauppinen, Anu
    ACTA OPHTHALMOLOGICA, 2021, 99
  • [43] THE PROLYL OLIGOPEPTIDASE INHIBITOR IPR-19 AMELIORATES COGNITIVE DEFICITS IN MOUSE MODELS OF SCHIZOPHRENIA
    R, Prades
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2017, 121 : 21 - 21
  • [44] Computational design development of prolyl oligopeptidase inhibitors
    Moitessier, Nicolas
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [45] Structure, function and biological relevance of prolyl oligopeptidase
    Szeltner, Zoltan
    Polgar, Laszlo
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2008, 9 (01) : 96 - 107
  • [46] Association of Prolyl Oligopeptidase with Conventional Neurotransmitters in the Brain
    Peltonen, Iida
    Myohanen, Timo T.
    Mannisto, Pekka T.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2011, 10 (03) : 311 - 318
  • [47] Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide
    Racys, Daugirdas Tomas
    Rea, Dean
    Fulop, Vilmos
    Wills, Martin
    BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (13) : 4775 - 4782
  • [48] Versatility of Prolyl Oligopeptidase B in Peptide Macrocyclization
    Sgambelluri, R. Michael
    Smith, Miranda O.
    Walton, Jonathan D.
    ACS SYNTHETIC BIOLOGY, 2018, 7 (01): : 145 - 152
  • [49] In search of physiological substrates of brain prolyl oligopeptidase
    Tenorio-Laranga, Jofre
    Mannisto, Pekka T.
    Garcia-Horsman, J. Arturo
    JOURNAL OF PEPTIDE SCIENCE, 2008, 14 (08) : 192 - 192
  • [50] Suggested functions for prolyl oligopeptidase:: A puzzling paradox
    Brandt, Inger
    Scharpe, Simon
    Lambeir, Anne-Marie
    CLINICA CHIMICA ACTA, 2007, 377 (1-2) : 50 - 61